Myriad Genetics (NASDAQ:MYGN) Issues FY 2025 Earnings Guidance

Myriad Genetics (NASDAQ:MYGN) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 0.070-0.110 for the period, compared to the consensus EPS estimate of 0.060. The company issued revenue guidance of $840.0 million-$860.0 million, compared to the consensus revenue estimate of $863.0 million.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on MYGN. StockNews.com downgraded Myriad Genetics from a “buy” rating to a “hold” rating in a research report on Saturday, March 1st. UBS Group dropped their target price on Myriad Genetics from $18.00 to $16.00 and set a “neutral” rating for the company in a research report on Tuesday, February 25th. Leerink Partners downgraded Myriad Genetics from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $30.00 to $21.00 in a research report on Monday, December 9th. Bank of America dropped their target price on Myriad Genetics from $13.00 to $11.00 and set an “underperform” rating for the company in a research report on Monday, March 3rd. Finally, Raymond James reiterated an “outperform” rating and issued a $19.00 target price (down from $27.00) on shares of Myriad Genetics in a research report on Tuesday, February 25th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Myriad Genetics presently has a consensus rating of “Hold” and an average price target of $21.82.

Myriad Genetics Trading Down 3.2 %

NASDAQ MYGN opened at $10.18 on Friday. The business has a 50 day simple moving average of $13.02 and a 200 day simple moving average of $18.55. Myriad Genetics has a one year low of $9.76 and a one year high of $29.30. The stock has a market capitalization of $929.53 million, a P/E ratio of -7.83 and a beta of 1.79. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.90 and a quick ratio of 1.73.

Myriad Genetics (NASDAQ:MYGN) last released its earnings results on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.12). Myriad Genetics had a negative return on equity of 4.51% and a negative net margin of 14.09%. The business had revenue of $210.60 million for the quarter, compared to analyst estimates of $210.35 million. During the same period in the prior year, the business earned ($0.12) EPS. Research analysts expect that Myriad Genetics will post -0.3 earnings per share for the current year.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.